The conjugacy of the use of synbiotic Maxilac® with the severity and duration of the course of COVID-19 in outpatient treatment

Despite the mass population immunization, total spread of COVID-19 pandemic once again made scientists around world doubt effectiveness currently existing methods prevention and treatment a novel coronavirus infection. The rationale for potentially new approach to preventive therapy using probiotic bacterial strains was presence bidirectional “gut-lung” axis, which interacts between these organs through transported soluble microbial metabolites in blood. study aimed determine relationship correction gut microbiota with polycomponent synbiotic Maxilac® clinical laboratory markers severity During open-label, prospective, observational 60 patients confirmed diagnosis COVID-19, moderate gastrointestinal symptoms were divided into 2 groups: 1st performed outpatient complex standard addition synbiotic, 2nd - without addition. All group 1 showed positive dynamics indicators severity, compared 2, where needed hospitalization due aggravation course A reduction duration revealed taking Maxilac®. reflecting indicate symbiotic’s usage as adjuvant possibility recommending its use